How many clinical trials are studying Pimavanserin?

4 recruiting trials in our tracked data involve Pimavanserin.

What conditions is Pimavanserin being studied for?

In our tracked recruiting trials, Pimavanserin is being studied in trials for Parkinson's disease, Depression, Parkinson's Disease Psychosis.

Pimavanserin: clinical trials recruiting now

Q: Is Pimavanserin FDA-approved?

Yes. According to the FDA drug label available through openFDA, Pimavanserin is an FDA-approved drug. Its FDA label carries a boxed warning.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Pimavanserin appears in the FDA drug-label database. Marketed as pimavanserin.
Boxed warning: The FDA label for Pimavanserin carries a boxed warning (the FDA's most serious warning). See the full label for details.

FDA-approved use

Pimavanserin capsule is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis [see Clinical Studies (14) ]. Pimavanserin capsule is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. (1)

FDA label via openFDA

Phase breakdown

Phase 2 2 Phase 4 2

Conditions being studied

Condition	Trials
Parkinson's disease · Pimavanserin for Parkinson's disease	3
Depression	2
Parkinson's Disease Psychosis	2
Dementia With Lewy Bodies	1
Major Depressive Disorder	1
Parkinson Disease	1
Schizophrenia	1

Recruiting trials involving Pimavanserin

Comparing Antipsychotic Medications in LBD Over Time
NCT05590637 · Phase: Phase 4 · Ages: No age limits stated · Sex: All (male and female) · 4 locations
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
NCT04373317 · Phase: Phase 4 · Ages: 40 Years and older · Sex: All (male and female) · 24 locations
Psilocybin Therapy for Depression in Parkinson's Disease
NCT06455293 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 1 location
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder
NCT06592833 · Phase: Phase 2 · Ages: 21 Years to 80 Years · Sex: All (male and female) · 1 location

Common questions

Is Pimavanserin FDA-approved?

Yes, marketed as pimavanserin. Its FDA label carries a boxed warning.

How many recruiting trials involve Pimavanserin?

4 recruiting trials across 7 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.